MabVax Therapeutics (MBVX) Positive Early Results in Race to Treat Pancreatic Cancer

NEW YORK, NY / ACCESSWIRE / August 29, 2016 / Pancreatic cancers are extremely complex and, unfortunately, highly lethal. According to the American Cancer Society the one-year relative survival rate is 20% and the five-year rate is 7% for all stages of pancreatic cancer combined. The 5-year survival rate for patients with metastatic pancreatic cancer is approximately 1 (one) percent. This is a horrific disease in which survivability for the vast majority of patients is measured in weeks and months.

Now, Nasdaq listed MabVax Therapeutics (MBVX) plans to release early research results that appear very positive, and the company has received a large investment from world-renowned biotech investor Dr. Phillip Frost.

The report on this exciting cancer research stock is available now at: http://microcapresearch.com/mabvax-therapeutics-mbvx-promising-early-results-treatment-pancreatic-cancer/

inquiries@microcapresearch.com

SOURCE: MicrocapResearch.com

ReleaseID: 444468